KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Inventory (2020 - 2025)

Historic Inventory for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to $108.5 million.

  • Esperion Therapeutics' Inventory rose 3550.1% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.5 million, marking a year-over-year increase of 3550.1%. This contributed to the annual value of $94.5 million for FY2024, which is 4399.07% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Inventory stood at $108.5 million, which was up 3550.1% from $114.5 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Inventory peaked at $114.5 million during Q2 2025, and registered a low of $20.0 million during Q1 2021.
  • Over the past 5 years, Esperion Therapeutics' median Inventory value was $45.7 million (recorded in 2023), while the average stood at $57.8 million.
  • Its Inventory has fluctuated over the past 5 years, first surged by 98799.57% in 2021, then crashed by 1303.13% in 2022.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Inventory stood at $34.4 million in 2021, then grew by 2.35% to $35.2 million in 2022, then soared by 86.42% to $65.6 million in 2023, then skyrocketed by 43.99% to $94.5 million in 2024, then grew by 14.87% to $108.5 million in 2025.
  • Its Inventory stands at $108.5 million for Q3 2025, versus $114.5 million for Q2 2025 and $99.3 million for Q1 2025.